Recent Finacing
Recent Raise
Atalanta Therapeutics develops branched di‑siRNA oligonucleotides to achieve durable, selective gene silencing across brain and spinal cord, advancing programs for Huntington’s disease, KCNT1 epilepsy, pain, partnered CNS targets.
